<DOC>
	<DOCNO>NCT02722473</DOCNO>
	<brief_summary>Cardiac arrest present major cause mortality well cause disability survive victims.In Europe , every year count 300,000 cardiac arrest responsible 250,000 death . Thus , less 20 % patient discharge home impair quality life associate symptom tiredness , stress , anxiety . The prognosis related initial cardiac rhythm present initiation resuscitation . Recent progress improvement mortality neurological outcome achieve last decade thanks systematic implementation period target temperature control 32 34 ° C patient benefit realization least one electrical external shock . There theoretical clinical argument think achieve way period target temperature control 32 34 ° C patient treat cardiac arrest non- shockable rhythm arrival also benefit procedure . However argument hypothesis include increase risk infection , worsen patient 's hemodynamic status benefit . To answer question , conduce randomize multicenter study test potential improvement neurological outcome procedure target temperature control 32.5 33.5 ° C patient . NSE-Ancillary Study HYPERION Trial determine impact neurospecific enolase ( brain biomarker ) two temperature target target temperature management ( 33°C 37°C ) cardiac arrest non-shockable rhythm .</brief_summary>
	<brief_title>NSE Ancillary Study The Therapeutic Hypothermia After Nonshockable Cardiac Arrest Trial .</brief_title>
	<detailed_description />
	<mesh_term>Heart Arrest</mesh_term>
	<mesh_term>Hypothermia</mesh_term>
	<criteria>Cardiac arrest nonshockable rhythm Glasgow Coma Scale score ≤8 . In patient receive sedative therapy ICU admission , Glasgow Coma Scale score assess emergency physician sedative therapy initiation use . Patient must randomize center participate ancillary study . Noflow time &gt; 10 min ( time collapse initiation external cardiac massage ) ; Lowflow time &gt; 60 min ( time initiation external cardiac massage return spontaneous circulation ) . Major hemodynamic instability ( define continuous epinephrine norepinephrine infusion flow rate &gt; 1 μg/Kg/min ) Time cardiac arrest study inclusion &gt; 300 min Moribund patient Child C cirrhosis liver Age &lt; 18 year Pregnant breastfeed woman Correctional facility inmate Previous inclusion another randomize clinical trial cardiac arrest day90 neurological outcome primary endpoint Patient without health insurance Decision patient next kin refuse study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>